Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

- Scientific Presentation at the 99th Annual Meeting of the American

Association for Cancer Research (AACR) -

TORONTO, April 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced presentations of further preclinical data from its two lead anticancer drugs at the Annual Meeting of the AACR in San Diego, CA, April 12-16, 2008.

The first presentation titled, "Preclinical development of LOR-253, a novel anticancer drug candidate that functions by modulating intracellular labile zinc homeostasis leading to cell cycle arrest," will be presented on April 16, 2008.

In this presentation, Lorus provided data on the preclinical development of LOR-253 (formerly known as LT-253), the Company's lead anticancer small molecule, with a novel cellular target. In animal studies, LOR-253 showed a favorable pharmacokinetic profile following intravenous dosing. A key finding of the study was the tissue distribution of LOR-253, where the drug was detected in tumor tissues in animal models, with significant affinity for lung and colon tissues. These results strongly support the potential treatment of these cancers with LOR-253, which has shown selective and potent anticancer activity in animal models of non-small cell lung cancer and colon cancer.

LOR-253 is currently in IND-enabling GLP toxicology studies, which are to be completed by mid-2008. Planning of a Phase I clinical trial in cancer indications for LOR-253 is in progress.

The second presentation, presented on April 13, 2008 titled, "GTI-2040 displays cooperative anti-tumor activity, when combined with chemotherapeutics and immunotherapeutics against human renal carcinoma xenografts".

This study reported preclinical results from combination therapies with
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... DUBLIN , July 10, 2014 ... the addition of the "International Photonic Integrated ... - Forecasts to 2019" report to their ... The concept of photonic integration traces ... twentieth century. The promise of photonic integration went ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and ... how the botulinum neurotoxin, a potential bioterrorism agent, survives ... through the human body. Their study, published February 24 ... of a neurotoxin together with its bodyguard, a protein ...
... The condensation of water is crucial to the operation of ... they are fueled by coal, natural gas or nuclear fuel. ... salty or brackish water. But there are still large gaps ... the surfaces used to turn steam back into water in ...
... 23, 2012 Springboard Enterprises has over a ... by women to potential investors and corporate partners. ... community-driven accelerator designed to fast track the growth ... healthcare IT companies from around the world. The ...
Cached Biology Technology:Disarming the botulinum neurotoxin 2Disarming the botulinum neurotoxin 3Making droplets drop faster 2Making droplets drop faster 3The Search Is On for the Next Big Life Science Innovation 2The Search Is On for the Next Big Life Science Innovation 3
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... Aware, Inc. (Nasdaq: AWRE ), a leading technology ... scheduled a conference call to discuss the company,s operating results ... February 3, 2011, at 5:00 p.m. Eastern Time. President and ... earnings conference call. This call is being webcast ...
... HARBIN, China, Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology ... WKBT ) ("Weikang" or the "Company"), a leading ... (TCM), Western prescription and OTC pharmaceuticals and other ... of China, today announced the completion of its ...
... SANDY, Utah, Feb. 9, 2011 Qqest and M2SYS ... announced a partnership that allows Qqest to offer TimeForce ... features of biometric identification technology at their PC. ... biometric platform technology to seamlessly interface with Qqest,s ...
Cached Biology News:Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: